Autologous CCR4 CAR T cells therapy (NIH)

N/A

Report date: 2025/07/12 20:00:06

Base Information

Drug NameAutologous CCR4 CAR T cells therapy (NIH)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionC-C chemokine receptor type 4 modulatorsT lymphocyte replacements
TargetsC-C chemokine receptor type 4
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralMycosis Fungoides +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralMycosis Fungoides +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A